title: Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
abstract: It has been widely reported that interleukin-8 (IL-8) is overexpressed in ovarian cyst fluid, ascites, serum, and tumor tissue from ovarian cancer (OVCA) patients, and elevated IL-8 expression correlates with a poor final outcome and chemosensitivity. However, the role of IL-8 expression in the acquisition of the chemoresistance phenotype and the underlining mechanisms of drug resistance in OVCA cells are not yet fully understood. Here we show that both exogenous (a relatively short period of treatment with recombination IL-8) and endogenous IL-8 (by transfecting with plasmid encoding for sense IL-8) induce cisplatin and paclitaxel resistance in non-IL-8-expressing A2780 cells, while deleting of endogenous IL-8 expression in IL-8-overexpressing SKOV-3 cells (by transfecting with plasmid encoding for antisense IL-8) promotes the sensitivity of these cells to anticancer drugs. IL-8-mediated resistance of OVCA cells exhibits decreased proteolytic activation of caspase-3. Meanwhile, the further study demonstrates that the chemoresistance caused by IL-8 is associated with increased expression of both multidrug resistance-related genes (MDR1) and apoptosis inhibitory proteins (Bcl-2, Bcl-xL, and XIAP), as well as activation of PI3K/Akt and Ras/MEK/ERK signaling. Therefore, modulation of IL-8 expression or its related signaling pathway may be a promising strategy of treatment for drug-resistant OVCA.
authors: Department of Immunology, Medical College of Chinese People's Armed Police Forces, Tianjin, People's Republic of China. wy68wy68@yahoo.com.cn
authors: Yue
authors: Y
authors: Wang
authors: Ye
authors: Y
authors: Qu
authors: Xiu Long
authors: XL
authors: Niu
authors: Wei Jia
authors: WJ
authors: Sun
authors: Xiao Lei
authors: XL
authors: Zhang
authors: Ling Zhi
authors: LZ
authors: Li
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001483:Base Sequence; D002945:Cisplatin / Q000627:therapeutic use*; D017931:DNA Primers; D019008:Drug Resistance, Neoplasm; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D016209:Interleukin-8 / Q000096:biosynthesis*; D010051:Ovarian Neoplasms / Q000473:pathology*; D017239:Paclitaxel / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; D017931:DNA Primers; D016209:Interleukin-8; D017239:Paclitaxel; D002945:Cisplatin